Glean occupies an unusual position in the AI landscape. It is not a model company — it does not train frontier AI. Instead, it sits on top of the models and indexes everything a company's employees touch: emails, Slack threads, Confluence pages, Salesforce records. The pitch is simple: one search box that actually knows your enterprise. The adoption curve has been steep.
That growth story creates genuine secondary-market interest. But interest and a sound investment thesis are different things. Secondary buyers in Glean need to answer four concrete questions before they commit capital.
Question 1: what does the last primary round actually tell you about fair value?
Glean's most recent disclosed primary round set a headline valuation that circulates widely in secondary conversations. The problem is that primary-round valuations are often set on preferred stock with liquidation preferences, participation rights, and other protective provisions. When you buy in the secondary market — whether through a direct transfer or an SPV — you are almost certainly buying common stock or a derivative of common stock. Common and preferred are not the same asset.
A useful discipline: model the common equity value explicitly. Take the headline valuation, apply the full liquidation stack as disclosed in public filings or inferred from known round terms, and estimate how much residual value flows to common holders at various exit multiples. If the secondary price implies a discount of 20–30% to the last primary round, that may still be a premium to the standalone common equity value once preferences are layered in.
Question 2: are you buying into an SPV or taking a direct transfer, and what does that mean for your ROFR exposure?
Most Glean secondary transactions are structured as SPV interests rather than direct share transfers. The reason is practical: direct transfers trigger the company's right of first refusal (ROFR), require board or administrator consent, and can take weeks to clear. An SPV transfer — where the legal holder of the shares does not change, only the economic beneficiary does — often sidesteps the ROFR trigger entirely.
That sounds cleaner, but it introduces a different set of risks. In an SPV you are not a shareholder of Glean. You hold a membership interest in a special purpose vehicle that holds Glean shares. You do not appear on the cap table. You will not receive communications from Glean directly. Your rights are whatever the SPV operating agreement says they are.
Read the operating agreement carefully before you wire funds. Key things to look for: GP carry structure, management fees if any, dissolution triggers, and what happens to your interest if Glean itself blocks a future transfer. We cover SPV economic terms in detail in our explainer on SPV fees and carry — worth reading before you evaluate any SPV-structured deal.
When a direct transfer makes sense
If you have the patience for ROFR clearance — typically 30 days from notice to waiver, though timelines vary by company charter — a direct transfer puts you on the cap table, gives you direct shareholder rights (limited as they may be for common holders), and removes GP carry from the equation. The trade-off is settlement speed and execution certainty. ROFR falls through if the company exercises its right, and some companies are unpredictable about when and whether they will. Model your net proceeds under both the SPV and direct paths before choosing.
Question 3: how concentrated is enterprise AI in your portfolio already?
If you already hold secondary exposure to OpenAI, Anthropic, Cohere, or Mistral, adding Glean may feel like diversification — different product layer, different revenue model, different customer base. In practice, the risk factors overlap significantly. All five names are highly exposed to: enterprise IT budget cycles, model commoditization risk (if models get cheaper and better, does Glean's index layer remain valuable?), and a financing environment where AI valuations remain sensitive to sentiment shifts.
Glean's differentiation argument is real. An application-layer company with deep enterprise integrations and high switching costs is structurally different from a model provider. But in a broad market correction or a sustained AI winter, correlation across all AI-adjacent names tends to converge. Size accordingly.
Question 4: what is the realistic liquidity path and on what timeline?
Secondary buyers in any private company need a realistic liquidity thesis. For Glean, the credible paths are: an IPO, an acquisition, or a company-run tender offer. Each has different implications for how and when you get paid.
- IPO: post-IPO lock-up periods typically run 180 days from listing. During that window, SPV holders may face additional restrictions depending on how the operating agreement handles lock-up obligations. You may not be able to sell immediately even after the IPO.
- Acquisition: strategic M&A can produce a clean cash exit, but acquirer stock consideration introduces its own holding period and market risk. Confirm with your attorney how your SPV interest converts in an all-stock deal.
- Tender offer: company-sponsored tenders are the most common current liquidity mechanism for mature private companies. They typically come at a valuation the company controls and with a participation cap — you may not be able to sell your full position.
None of these paths has a known date. Any secondary investment in Glean should be sized as if you may hold it for three to five years with no interim liquidity. If that holding period would create cash flow problems or meaningful concentration issues, it is worth revisiting position size before you commit.
What to do next
Glean is a legitimate business with a strong adoption trajectory. Secondary exposure can make sense for accredited investors who have done the structural and valuation work. The errors that cost buyers money are not usually about picking the wrong company — they are about buying the wrong instrument, at the wrong price, in the wrong size, without a realistic liquidity plan.
At Limen Markets, current Glean indications are listed with confirmed seller-side supply, disclosed structure (SPV or direct), and pricing refreshed hourly. If you want to compare current pricing against the last known primary mark, the marketplace is the right starting point. We also recommend reading our preferred-vs-common buyer guide before you finalize your view on fair value.
Browse current Glean listings and live indications at /marketplace.